Middle East & Africa Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, an

Middle East & Africa Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Route of Administration (Injectable Drug Delivery, Oral Drug Delivery, Transmucosal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, and Ocular Drug Delivery), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and End User (Hospitals and Clinics, Home Care Settings, and Other End Users)
The Middle East & Africa drug delivery market is expected to grow from US$ 88,195.85 million in 2023 to US$ 1,19,118.15 million by 2028. It is estimated to register a CAGR of 6.2% from 2023 to 2028.

Growing Demand for Noninvasive Drug Delivery Systems Fuel Middle East & Africa Drug Delivery Market

Companies operating in the drug delivery systems market constantly focus on strategic developments such as collaboration, agreements, partnerships, and new product launches, which help them improve their sales. The new product launches are mainly directed toward increased security, user-friendly features, better dosing capabilities, etc., to attract a large patient base. Through improved dosing capabilities, drug delivery systems complement the therapeutic outcomes and increase the potential of disease management in home care settings. There are a few noteworthy developments in the drug delivery market. In November 2020, Medtronic launched InPen integrated with real-time Guardian Connect CGM data. The product provides real-time glucose readings alongside insulin dose information. In March 2021, Jabil Healthcare, a division of Jabil Inc., entered a strategic collaboration agreement with E3D, a global drug delivery device company and a member of the Elcam Medical Group. Under the terms of this deal, Jabil has secured exclusive rights to use E3D’s reusable mechanical auto-injector for the development of high-volume reusable auto-injector and connected variants. In April 2021, KINDEVA DRUG DELIVERY collaborated with Cambridge Healthcare Innovations Limited (CHI) to develop and commercialize CHI’s ?eolus dry-powder inhaler (DPI) platform technology. In November 2021, Ypsomed launched YpsoMate and claimed it as the world’s first auto-injector for prefilled syringes with integrated connectivity. YpsoMate can be used for self-administration of therapeutics. In June 2022, EVERSANA and Accord BioPharma partnered to support the launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults. In October 2022, Aenova Group and Microcaps partnered to accelerate and improve the process of development and production of pharmaceuticals, food supplements, and many other products. The Aenova Group is a globally operating contract manufacturer and development service provider for the pharmaceutical and healthcare industries. Microcaps is an innovative Swiss start-up company that has developed a novel, high-precision, and scalable microencapsulation technology. Together, they focus on offering a broader range of new product development and life cycle management solutions for microcapsule and conventional capsule formulations, such as enhanced taste masking, controlled release, targeted release, increased bioavailability, and improved active pharmaceutical ingredient stability. In March 2023, Stevanato Group collaborated with Recipharm to develop and manufacture pre-fillable syringes that would be integrated into a new soft mist inhaler for inhaling sensitive biological products. The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm’s proprietary soft mist inhalers.

Thus, the rise in strategic developments and product launches is expected to invite new growth trends in the Middle East & Africa drug delivery market in the coming years.

Middle East & Africa Drug Delivery Market Overview

The drug delivery market in the Middle East & Africa is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa. The market growth in this region is attributed to the increasing prevalence of diabetes and other chronic diseases and rising number of initiatives led by the government and other organizations to spread awareness among people. Additionally, increasing efforts of companies toward adopting drug delivery technology are contributing to the growth of the drug delivery market in the Middle East & Africa.

Middle East & Africa Drug Delivery Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Drug Delivery Market Segmentation

The Middle East & Africa drug delivery market is segmented into route of administration, distribution channel, end user, and country.

Based on route of administration, the Middle East & Africa drug delivery market is segmented into injectable drug delivery, oral drug delivery, transmucosal drug delivery, topical drug delivery, implantable drug delivery, and ocular drug delivery. The injectable drug delivery segment held a larger share of the Middle East & Africa drug delivery market in 2023.

Based on distribution channel, the Middle East & Africa drug delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the Middle East & Africa drug delivery market in 2023.

Based on end user, the Middle East & Africa drug delivery market is segmented into hospitals and clinics, home care settings, and other end user. The hospitals and clinics segment held the largest share of the Middle East & Africa drug delivery market in 2023.

Based on country, the Middle East & Africa drug delivery market is segmented into the UAE, Saudi Arabia, South Africa, the Rest of Middle East & Africa. The UAE dominated the share of the Middle East & Africa drug delivery market in 2023.

Bausch Health Companies Inc, Baxter International Inc, Becton Dickinson and Co, Boehringer Ingelheim International GmbH, Boston Scientific Corp, GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG, Novo Nordisk AS, and Pfizer Inc are the leading companies operating in the Middle East & Africa drug delivery market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa drug delivery market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa drug delivery market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.